IL252426A0 - Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal - Google Patents
Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signalInfo
- Publication number
- IL252426A0 IL252426A0 IL252426A IL25242617A IL252426A0 IL 252426 A0 IL252426 A0 IL 252426A0 IL 252426 A IL252426 A IL 252426A IL 25242617 A IL25242617 A IL 25242617A IL 252426 A0 IL252426 A0 IL 252426A0
- Authority
- IL
- Israel
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- sequence lacking
- modified bacteriophage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 | |
| PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL252426A0 true IL252426A0 (en) | 2017-07-31 |
Family
ID=55273507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252426A IL252426A0 (en) | 2014-12-03 | 2017-05-22 | Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (https=) |
| EP (1) | EP3227313B1 (https=) |
| JP (2) | JP6730988B2 (https=) |
| KR (1) | KR20170085132A (https=) |
| CN (1) | CN107250154A (https=) |
| AR (1) | AR102890A1 (https=) |
| AU (1) | AU2015358504A1 (https=) |
| BR (1) | BR112017011530A2 (https=) |
| CA (1) | CA2969128A1 (https=) |
| DK (1) | DK3227313T3 (https=) |
| EA (1) | EA201791212A1 (https=) |
| ES (1) | ES2910017T3 (https=) |
| IL (1) | IL252426A0 (https=) |
| MX (1) | MX2017007059A (https=) |
| PH (1) | PH12017501004A1 (https=) |
| PL (1) | PL3227313T3 (https=) |
| PT (1) | PT3227313T (https=) |
| SG (1) | SG11201704427YA (https=) |
| TW (1) | TW201632542A (https=) |
| WO (1) | WO2016090022A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2857539C (en) | 2011-11-29 | 2021-08-03 | Neurophage Pharmaceuticals, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| DK2906235T3 (en) | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| AU2014274253B2 (en) | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| BR112017011530A2 (pt) | 2014-12-03 | 2018-03-13 | Proclara Biosciences Inc | polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação |
| WO2019241628A1 (en) * | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
| AU2023403257A1 (en) | 2022-12-02 | 2025-06-12 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| CN100522242C (zh) | 2001-02-19 | 2009-08-05 | 默克专利有限公司 | 具有降低的免疫原性的人工蛋白质 |
| KR20030082962A (ko) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| DK1853285T3 (da) | 2005-02-01 | 2011-06-27 | Univ Ramot | Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia |
| EP1991261A2 (en) | 2006-02-15 | 2008-11-19 | Ramot at Tel-Aviv University Ltd. | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| AU2007275258A1 (en) | 2006-07-21 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| KR101485202B1 (ko) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| EP2303315A1 (en) | 2008-05-22 | 2011-04-06 | Ramot at Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| NZ592928A (en) | 2008-11-24 | 2012-12-21 | Univ Ramot | Method for treating parkinson' s disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| WO2012125555A1 (en) | 2011-03-11 | 2012-09-20 | Ramot At Tel-Aviv University Ltd. | Method for treating neurodegenerative tauopathy |
| CA2857539C (en) | 2011-11-29 | 2021-08-03 | Neurophage Pharmaceuticals, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| DK2906235T3 (en) * | 2012-10-02 | 2017-09-25 | Proclara Biosciences Inc | USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS |
| AU2014274253B2 (en) * | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| BR112017011530A2 (pt) | 2014-12-03 | 2018-03-13 | Proclara Biosciences Inc | polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação |
-
2015
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en not_active Ceased
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko not_active Withdrawn
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja not_active Expired - Fee Related
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016090022A1 (en) | 2016-06-09 |
| PH12017501004A1 (en) | 2017-12-18 |
| ES2910017T3 (es) | 2022-05-11 |
| MX2017007059A (es) | 2018-05-02 |
| AU2015358504A8 (en) | 2017-07-13 |
| US11723951B2 (en) | 2023-08-15 |
| KR20170085132A (ko) | 2017-07-21 |
| JP2020073610A (ja) | 2020-05-14 |
| AU2015358504A1 (en) | 2017-06-29 |
| PL3227313T3 (pl) | 2022-05-09 |
| US10722551B2 (en) | 2020-07-28 |
| TW201632542A (zh) | 2016-09-16 |
| JP2017538407A (ja) | 2017-12-28 |
| WO2016090022A9 (en) | 2016-08-25 |
| US20210015895A1 (en) | 2021-01-21 |
| CA2969128A1 (en) | 2016-06-09 |
| JP6730988B2 (ja) | 2020-07-29 |
| SG11201704427YA (en) | 2017-06-29 |
| PT3227313T (pt) | 2022-04-12 |
| EP3227313A1 (en) | 2017-10-11 |
| BR112017011530A2 (pt) | 2018-03-13 |
| AR102890A1 (es) | 2017-03-29 |
| DK3227313T3 (da) | 2022-04-19 |
| WO2016090022A8 (en) | 2017-06-22 |
| EP3227313B1 (en) | 2022-02-09 |
| EA201791212A1 (ru) | 2018-01-31 |
| US20180207231A1 (en) | 2018-07-26 |
| CN107250154A (zh) | 2017-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258041B (en) | A new endolysin polypeptide | |
| ZA201802261B (en) | Polypeptides | |
| IL254965A0 (en) | fusion proteins | |
| IL254577A0 (en) | polypeptides | |
| EP3371349A4 (en) | Conditionally active polypeptides | |
| IL252426A0 (en) | Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| SG11201706882VA (en) | Polypeptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| SG11201509647WA (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
| GB201520583D0 (en) | Peptides | |
| IL248276A0 (en) | Carbohydrate binding proteins | |
| GB201600512D0 (en) | Recombinant protein production | |
| GB201520536D0 (en) | Peptides | |
| GB201520544D0 (en) | Peptides | |
| GB201708277D0 (en) | A Recombinant protein | |
| HK1249520A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| GB201622073D0 (en) | Improved recombinant protein production system | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201520571D0 (en) | Peptides | |
| GB201520534D0 (en) | Peptides | |
| GB201520582D0 (en) | Peptides | |
| GB201520598D0 (en) | Peptides | |
| GB201520577D0 (en) | Peptides | |
| GB201520535D0 (en) | Peptides |